<SEC-DOCUMENT>0001193125-18-330650.txt : 20181120
<SEC-HEADER>0001193125-18-330650.hdr.sgml : 20181120
<ACCEPTANCE-DATETIME>20181119215336
ACCESSION NUMBER:		0001193125-18-330650
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20181119
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20181120
DATE AS OF CHANGE:		20181119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01011
		FILM NUMBER:		181194218

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d658002d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): November&nbsp;19, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g658002g48z05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CVS HEALTH CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delaware
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of Incorporation) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-01011</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">05-0494040</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>One CVS Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Woonsocket, Rhode Island</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02895</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (401)
<FONT STYLE="white-space:nowrap">765-1500</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent applicable, the information in Item 8.01 of this Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> is incorporated by reference in this Item&nbsp;5.02.</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the closing of the proposed acquisition of Aetna Inc. (the &#147;<U>Acquisition</U>&#148;), all of the required change in control filings
were submitted to 28 state insurance departments in January 2018. CVS Health Corporation (&#147;<U>CVS Health</U>&#148;) has received approval from 26 of the 28 state departments of insurance. CVS Health has made significant progress and is in the
final stages of the approval process with the remaining two states. CVS Health is confident that these remaining approvals will be secured. As a result, the Acquisition is now expected to close after the Thanksgiving holiday. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;19, 2018, following the November 6, 2018 filing with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) of CVS Health&#146;s
Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended September&nbsp;30, 2018 and in anticipation of the closing of the proposed Acquisition, CVS Health announced Eva&nbsp;C. Boratto has been appointed
Executive Vice President and Chief Financial Officer and James&nbsp;D. Clark has been appointed as CVS Health&#146;s Senior Vice President &#150; Controller and Chief Accounting Officer, effective as of that date. CVS Health previously announced, in
Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on October&nbsp;10, 2018 and October&nbsp;22, 2018, that Ms.&nbsp;Boratto and Mr.&nbsp;Clark would be appointed to these positions at the close of the
Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health had previously announced, in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on
June&nbsp;6, 2018, that David&nbsp;M. Denton, Executive Vice President and Chief Financial Officer of CVS Health, would be leaving CVS Health at the closing of the Acquisition. CVS Health announced on November&nbsp;19, 2018 that Mr.&nbsp;Denton
would be separated under the terms of his separation agreement effective as of that date. Other than the change to Mr.&nbsp;Denton&#146;s departure date, the previously announced terms of Mr.&nbsp;Denton&#146;s separation remain unchanged. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for
informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the
solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
No offer of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the transaction, CVS Health filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> with the Securities and SEC,
which includes a joint proxy statement of CVS Health and Aetna that also constitutes a prospectus of CVS Health. The registration statement was declared effective by the SEC on February&nbsp;9, 2018 (the &#147;<U>Registration Statement</U>&#148;),
and CVS Health and Aetna commenced mailing the definitive joint proxy statement/prospectus to stockholders of CVS Health and shareholders of Aetna on or about February&nbsp;12, 2018 (the &#147;<U>Joint Proxy Statement/Prospectus</U>&#148;) and the
special meeting of the stockholders of CVS Health and the shareholders of Aetna was held on March&nbsp;13, 2018. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER
DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the Registration Statement and the definitive
Joint Proxy Statement/Prospectus and other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by CVS Health are available free of charge
within the Investors section of CVS Health&#146;s Web site at http://www.cvshealth.com/investors or by contacting CVS Health&#146;s Investor Relations Department at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">800-201-0938.</FONT></FONT> Copies of the documents filed with the SEC by Aetna are available free of charge on Aetna&#146;s internet website at http://www.Aetna.com or by contacting
Aetna&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">860-273-0896.</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary
Statement Regarding Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Securities Litigation Reform Act of 1995 (the &#147;<U>Reform Act</U>&#148;) provides a
safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation (&#147;<U>CVS Health</U>&#148;) or Aetna, Inc. (&#147;<U>Aetna</U>&#148;). This communication may contain forward-looking statements within the meaning of the
Reform Act. You can generally identify forward-looking statements by the use of forward-looking terminology such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148;
&#147;evaluate,&#148; &#147;expect,&#148; &#147;explore,&#148; &#147;forecast,&#148; &#147;guidance,&#148; &#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;outlook,&#148; &#147;plan,&#148; &#147;potential,&#148;
&#147;predict,&#148; &#147;probable,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;view,&#148; or &#147;will,&#148; or the negative thereof or other variations thereon or comparable terminology. These forward-looking
statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond CVS Health&#146;s and Aetna&#146;s control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this communication regarding CVS Health and Aetna that are forward-looking, including CVS Health&#146;s and Aetna&#146;s projections as to the
closing date of the transactions contemplated by the Agreement and Plan of Merger, dated as of December&nbsp;3, 2017 (&#147;<U>Merger Agreement</U>&#148;), among CVS Health, Aetna and Hudson Merger Sub Corp., a wholly-owned subsidiary of CVS Health
(the &#147;<U>transaction</U>&#148;), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the anticipated benefits of the transaction, the impact of the transaction on CVS Health&#146;s and
Aetna&#146;s businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health&#146;s common stock of CVS Health stockholders and Aetna shareholders at closing, the aggregate amount of
indebtedness of CVS Health following the closing of the transaction, CVS Health&#146;s expectations regarding debt repayment and its debt to capital ratio following the closing of the transaction, CVS Health&#146;s and Aetna&#146;s respective share
repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined companies&#146; pharmacy benefit business, the synergies from the transaction, and CVS Health&#146;s,
Aetna&#146;s and/or the combined company&#146;s future operating results, are based on CVS Health&#146;s and Aetna&#146;s managements&#146; estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many
of which are beyond their control. In particular, projected financial information for the combined businesses of CVS Health and Aetna is based on estimates, assumptions and projections and has not been prepared in conformance with the applicable
accounting requirements of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-X&nbsp;relating</FONT> to pro forma financial information, and the required pro forma adjustments have not been applied and are not reflected therein. None of this
information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk factors related to the transaction could cause actual future results and other future events to
differ materially from those currently estimated by management, including, but not limited to: the timing to consummate the proposed transaction; the risk that a regulatory approval that may be required for the proposed transaction is delayed, is
not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may not be satisfied; the outcome of litigation related to the transaction; the ability to achieve the
synergies and value creation contemplated; CVS Health&#146;s ability to promptly and effectively integrate Aetna&#146;s businesses; and the diversion of and attention of management of both CVS Health and Aetna on transaction-related issues. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this communication may contain forward-looking statements regarding CVS Health&#146;s or
Aetna&#146;s respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or Aetna or that they
currently believe to be immaterial also may cause CVS Health&#146;s or Aetna&#146;s actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective businesses, CVS Health&#146;s ability
to complete the transaction and/or CVS Health&#146;s ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the
transaction and/or CVS Health or Aetna, CVS Health&#146;s ability to successfully complete the transaction and/or realize the expected benefits from the transaction. Additional information concerning these risks, uncertainties and assumptions can be
found in CVS Health&#146;s and Aetna&#146;s respective filings with the SEC, including the risk factors discussed in &#147;Item 1.A. Risk Factors&#148; in CVS Health&#146;s and Aetna&#146;s most recent Annual Reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;as</FONT> updated by their Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and future filings with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue reliance on any CVS Health&#146;s and Aetna&#146;s forward-looking statements. These forward-looking statements are and
will be based upon management&#146;s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither CVS Health nor Aetna assumes any duty to update or revise
forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information furnished pursuant
to Item 7.01 of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> shall not be deemed to be &#147;filed&#148; for the purpose of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange
Act</U>&#148;), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall
be expressly set forth by specific reference in such filing. The furnishing of this information is not intended to constitute a determination by CVS Health that the information is material or that the dissemination of the information is required by
Regulation FD. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CVS HEALTH CORPORATION</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Colleen M. McIntosh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Colleen M. McIntosh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President, Corporate</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Secretary and Assistant General Counsel</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated: November&nbsp;19, 2018</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g658002g48z05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g658002g48z05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$*17AI9@  34T *@    @ ! $[  (
M   5   (2H=I  0    !   (8)R=  $    J   0V.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $5U9V5N:6$@
M2')Y<V]U;&QA:VES    !9 #  (    4   0KI $  (    4   0PI*1  (
M   #-#8  )*2  (    #-#8  .H<  <   @,   (H@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 #(P,3@Z,3$Z,3D@,3$Z-#,Z,C8
M,C Q.#HQ,3HQ.2 Q,3HT,SHR-@   $4 =0!G &4 ;@!I &$ ( !( '( >0!S
M &\ =0!L &P 80!K &D <P   /_A"R=H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED)S\^#0H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W
M-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT
M<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F
M-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T
M93XR,#$X+3$Q+3$Y5#$Q.C0S.C(V+C0V,#PO>&UP.D-R96%T941A=&4^/"]R
M9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U
M:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN
M<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC
M<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O
M,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D9CIL:3Y%=6=E;FEA($AR
M>7-O=6QL86MI<SPO<F1F.FQI/CPO<F1F.E-E<3X-"@D)"3PO9&,Z8W)E871O
M<CX\+W)D9CI$97-C<FEP=&EO;CX\+W)D9CI21$8^/"]X.GAM<&UE=&$^#0H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(#P_>'!A8VME="!E;F0])W<G/S[_VP!#
M  <%!08%! <&!08(!P<("A$+"@D)"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8
M(BXB)2@I*RPK&B O,R\J,B<J*RK_VP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_
MP  1"  I -0# 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%
M!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q
M%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*C
MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ
M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M2;NTDO,^C20.II-P]1^=>*>$/B]J+:G!9>)#%/!.X072)L:,GID#C%:_Q?\
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MFYZUW5%.,5'1&-:O5KRYJLKF%X3\+Q>$=%_LVUOKZ^C$C2"6^E\R09_A!P,
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:*]/HH 9!&(;>.(,S!%"[G.2<<9-%/HH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
